Validation of a novel molecular RPA classification in glioblastoma (GBM-molRPA) treated with chemoradiation: A multi-institutional collaborative study

Chan Woo Wee, Il Han Kim, Chul Kee Park, Jin Wook Kim, Yun Sik Dho, Fumiharu Ohka, Kosuke Aoki, Kazuya Motomura, Atsushi Natsume, Nalee Kim, Chang Ok Suh, Jong Hee Chang, Se Hoon Kim, Won Kyung Cho, Do Hoon Lim, Do Hyun Nam, Jung Won Choi, In Ah Kim, Chae Yong Kim, Young Taek OhOyeon Cho, Woong Ki Chung, Sung Hwan Kim, Eunji Kim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background and purpose: A novel molecular recursive partitioning analysis classification has recently been reported integrating the MGMT promoter methylation (MGMTmeth) and IDH1 mutation (IDH1mut) status for glioblastoma (GBM-molRPA) patients treated with temozolomide-based chemoradiation. The current study was initiated to validate the model in a multi-institutional study. Materials and methods: Four-hundred seventy-one newly diagnosed GBM patients (validation cohort) were allocated to classes I–III of the previously reported GBM-molRPA model. Of the patients, 15.7%, 56.1%, and 28.2% patients were GBM-molRPA class I, II, and III, respectively. MGMTmeth and IDH1mut were observed in 32.3 and 8.8% of patients, respectively. In the training plus validation cohort of 692 patients, 16.2%, 60.8%, and 23.0% patients were class I, II, and III, respectively. Results: The median follow-up for survivors and the median survival (MS) of patients was 23.3 and 18.4 months, respectively. The MS for GBM-molRPA class I, II, and III was 49.7 (95% CI, 22.8–76.6), 19.2 (95% CI, 16.2–22.1), and 13.8 months (95% CI, 11.8–15.4) (P <.001 for all comparisons) in the validation cohort. In the training plus validation cohort, the MS was 58.5 (95% CI, 40.7–76.3), 21. (95% CI, 18.6–23.3), and 14.3 months (95% CI, 12.5–16.1) (P <.001 for all comparisons) for class I, II, and III, respectively. Conclusion: The GBM-molRPA is a valid model. This GBM-molRPA classification can be useful in clinics and guiding patient stratification in future clinical trials.

Original languageEnglish
Pages (from-to)347-351
Number of pages5
JournalRadiotherapy and Oncology
Volume129
Issue number2
DOIs
Publication statusPublished - 2018 Nov

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Wee, C. W., Kim, I. H., Park, C. K., Kim, J. W., Dho, Y. S., Ohka, F., Aoki, K., Motomura, K., Natsume, A., Kim, N., Suh, C. O., Chang, J. H., Kim, S. H., Cho, W. K., Lim, D. H., Nam, D. H., Choi, J. W., Kim, I. A., Kim, C. Y., ... Kim, E. (2018). Validation of a novel molecular RPA classification in glioblastoma (GBM-molRPA) treated with chemoradiation: A multi-institutional collaborative study. Radiotherapy and Oncology, 129(2), 347-351. https://doi.org/10.1016/j.radonc.2018.09.001